Novartis takes aim at risky Parkinson’s target with $1.5bn UCB dealNovartis has licensed a potential drug for Parkinson’s from Belgium’s UCB that it thinks could be the first Share XNovartis takes aim at risky Parkinson’s target with $1.5bn UCB dealhttps://pharmaphorum.com/news/novartis-takes-aim-at-risky-parkinsons-target-with-1-5bn-ucb-deal/
GSK pumps £30m into a new Oxford University partnershipGlaxoSmithKline has formed a five-year partnership with Oxford University to set up a new institute that will apply Share XGSK pumps £30m into a new Oxford University partnershiphttps://pharmaphorum.com/news/gsk-pumps-30m-into-a-new-oxford-university-institute/
Dyno attracts $1.6bn gene therapy deal with AstellasAstellas has signed another bolt-on deal to build its gene therapy pipeline, agreeing a deal with Dyno Therapeutics Share XDyno attracts $1.6bn gene therapy deal with Astellashttps://pharmaphorum.com/news/dyno-attracts-1-6bn-gene-therapy-deal-with-astellas/
Sanofi snaps up acne vaccine developer Origimm BioSanofi has added to its vaccine pipeline with an agreement to acquire Austria’s Origimm Biotechnology and its vaccine-based Share XSanofi snaps up acne vaccine developer Origimm Biohttps://pharmaphorum.com/news/sanofi-snaps-up-acne-vaccine-developer-origimm-bio/
GSK poaches Pfizer exec Dormitzer as new vaccines R&D chiefGlaxoSmithKline has found a replacement for head of vaccines R&D Emmanuel Hanon, who left the company for a Share XGSK poaches Pfizer exec Dormitzer as new vaccines R&D chiefhttps://pharmaphorum.com/news/gsk-poaches-pfizer-exec-dormitzer-as-new-vaccines-chief/
Report suggests UK’s national vaccine facility is on the blockThe UK’s Vaccines Manufacturing and Innovation Centre (VMIC) – unveiled with fanfare by the government in 2018 – Share XReport suggests UK’s national vaccine facility is on the blockhttps://pharmaphorum.com/news/report-suggests-uks-national-vaccine-facility-is-on-the-block/
Pharma pledges rapid response to Omicron COVID variantWith governments around the world announcing measures to curb the new B.1.1.529 variant of COVID-19 – now christened Share XPharma pledges rapid response to Omicron COVID varianthttps://pharmaphorum.com/news/pharma-pledges-rapid-response-to-omicron-covid-variant/
Fall in efficacy of Merck’s molnupiravir puts Pfizer in driver’s seatMerck & Co has reported new data with its oral antiviral molnupiravir that suggests it is not as Share XFall in efficacy of Merck’s molnupiravir puts Pfizer in driver’s seathttps://pharmaphorum.com/news/fall-in-efficacy-of-mercks-molnupiravir-puts-pfizer-in-drivers-seat/
Could safety scupper Ionis, Pfizer’s cholesterol drug vupanorsen?Ionis has reported phase 2b trial data for its Pfizer-partnered antisense drug vupanorsen for cholesterol lowering that showed Share XCould safety scupper Ionis, Pfizer’s cholesterol drug vupanorsen?https://pharmaphorum.com/news/could-safety-scupper-ionis-pfizers-cholesterol-drug-vupanorsen/
